Differential pricing policies for covid-19 vaccinations

That this House believes that the UK has both a moral and practical incentive to see the whole world vaccinated against covid-19; is concerned that differential pricing by pharmaceutical companies gravitates against that ambition by asking the poorest countries to pay more than the richest; notes that AstraZeneca is charging the European Union $2 per vaccine compared to $7 for Uganda; further notes that the Serum Institute which produces the AstraZeneca vaccine under licence, is charging $5 per vaccine in South Africa; is concerned that pharmaceutical companies which have received UK public financial support are making profits at the expense of the poorest countries; calls on the UK Government to ensure pharmaceutical companies revisit their differential pricing policies, and commit to not making a profit from the pandemic.